You are here
Generic Augmentin Clears FDA Hurdle
JERUSALEM--(BUSINESS WIRE)--March 12, 2004--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA - News) announced today that the U.S. Food and Drug Administration has granted approval for the company's ANDA for Amoxicillin/Clavulanate Potassium For Oral Suspension, 600 mg/42.9 mg/5 mL. A launch date has not yet been finalized.
Teva's Amoxicillin/Clavulanate Potassium FOS, 600 mg/42.9 mg/5 mL is the AB-rated generic equivalent of GlaxoSmithKline's antibiotic Augmentin® ES-600.
Source: Teva Pharmaceutical Industries
Drug Maintained Its Effect After Six Months of Use
First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time